title: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation.
abstract: These updated guidelines are based on the first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in the years 2005 and 2006. For this 2015 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations which are clinically and scientifically relevant. They are intended to be used by all physicians diagnosing and treating patients with schizophrenia. Based on the first version of these guidelines a systematic review, as well as a data extraction from national guidelines have been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and subsequently categorised into six levels of evidence (A-F) and five levels of recommendation (1-5). This third part of the updated guidelines covers the management of the following specific treatment circumstances: comorbid depression, suicidality, various comorbid substance use disorders (legal and illegal drugs), and pregnancy and lactation. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of patients with schizophrenia.
authors.affiliation: Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University , Munich , Germany.
authors.forename: Alkomiet
authors.initials: A
authors.lastname: Hasan
authors.forename: Peter
authors.initials: P
authors.lastname: Falkai
authors.forename: Thomas
authors.initials: T
authors.lastname: Wobrock
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Lieberman
authors.forename: Birte
authors.initials: B
authors.lastname: Glenthøj
authors.forename: Wagner F
authors.initials: WF
authors.lastname: Gattaz
authors.forename: Florence
authors.initials: F
authors.lastname: Thibaut
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Möller
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001689:Biological Psychiatry / Q000379:methods*; D001942:Breast Feeding; D003863:Depression / Q000628:therapy*; D019468:Disease Management; D004359:Drug Therapy, Combination; D004565:Electroconvulsive Therapy; D019317:Evidence-Based Medicine / Q000379:methods; D005260:Female; D006801:Humans; D007391:International Cooperation; D007774:Lactation; D011247:Pregnancy; D011248:Pregnancy Complications / Q000628:therapy*; D011613:Psychotherapy; D012559:Schizophrenia / Q000628:therapy*; D016540:Smoking Cessation; D019966:Substance-Related Disorders / Q000628:therapy*; D050781:Transcranial Magnetic Stimulation; D000092864:Suicide Prevention
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents
keywords: comorbid depression; comorbid substance use disorder; pregnancy; schizophrenia; suicidality